MedTrace Logo

Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults

NCT00482001 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-05-10

Study results available
· View outcomes & findings →

Summary

The goal of the study is to assess the role of cholinesterase inhibitors in affecting the driving ability of cognitively intact seniors using driving simulators. We hypothesize that the use of a cholinesterase inhibitor for two weeks will be associated with improvement in safe driving behavior on a simulated driving task.

Conditions

Interventions

DRUG

donepezil

DRUG

Placebo (cornstarch)

Sponsors & Collaborators

  • University of Toronto

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Mark Rapoport, MD, FRCPC · University of Toronto

  • Michel Bedard, PhD · Lakehead University

  • Nathan Herrmann, MD, FRCPC · University of Toronto

  • Krista Lanctot, PhD · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00482001 on ClinicalTrials.gov